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Heterogeneity-q13.1 has been linked to type 2 diabetes mellitus (T2DM) in multiple studies. We
screened a 5.795-Mb region for diabetes-related susceptibility genes in a Caucasian cohort of 310 controls
and 300 cases with T2DM and end-stage renal disease (ESRD), testing 390 SNPs for association with T2DM-
ESRD. The most signiﬁcant SNPs were found in the perigenic regions: HNF4A (hepatocyte nuclear factor 4),
SLC12A5 (potassium-chloride cotransporter member 5), CDH22 (cadherin-like 22), ELMO2 (engulfment and
cell motility 2), SLC13A3 (sodium-dependent dicarboxylate transporter member 3), and PREX1 (phospha-
tidylinositol 3,4,5-triphosphate-dependent RAC exchanger 1). Haplotype analysis found six haplotype blocks
globally associated with disease (pb0.05). We replicated the PREX1 SNP association in an independent case-
control T2DM population and inferred replication of CDH22, ELMO2, SLC13A3, SLC12A5, and PREX1 using in
silico perigenic analysis of two T2DM Genome-Wide Association Study data sets. We found substantial
heterogeneity between study results.
© 2008 Elsevier Inc. All rights reserved.The human 20q12-q13.1 region has been linked to type 2 diabetes
mellitus (T2DM) in multiple studies. In our laboratory, efforts to
identify diabetogenic genes have included ﬁne-mapping and physical-
mapping studies [1–3] and analysis of speciﬁc genes such as protein
kinase C binding protein 1 (PRKCBP1, ofﬁcial symbol ZMYND8),
hepatocyte nuclear factor 4 (HNF4A), GLUT10 glucose transporter
(SLC2A10) [2–5], and multiple additional genes [4–6]. While other
investigators have reported evidence for association of HNF4A with
T2DM [7,8], we have observed limited evidence for a signiﬁcant
contribution of HNF4A to T2DM susceptibility in our population [9].
We have reported evidence of association with the PTPN1 gene with
T2DM and measures of glucose homeostasis [10,11]. Recently, efforts
to identify novel diabetes susceptibility genes in the region have been
reported in a Japanese sample [12] and in a combined U.K./Ashkenazi
Jewish sample [13]. Systematic map coverage of previously linked
genomic regions provides a targeted strategy for determining genetic
contributions to disease susceptibility.
As the availability of high-throughput methods for genotyping has
increased and costs have dropped, high-density SNPmapshave emergedckyj).
l rights reserved.as a practical approach for identifying genes through systematic
associationanalysis of extendedchromosomal regionsand, very recently,
whole genome analysis. Systematic genotyping over contiguous regions
has suggested that much of the genome is organized into discrete blocks
of variable length deﬁned by SNPs in high linkage disequilibrium (LD)
with limited haplotype diversity [14,15]. The haplotype block structure
of the genome in combination with dense SNP maps can potentially
facilitate detection of disease-associated genes (e.g., [16–18]).
The use of extended, high-density SNP maps enhances physical
coverage of positional candidate genome segments and, with judicious
sampling of themarker allele frequency spectrum, canpreserve nominal
power to detect common variants across a signiﬁcant proportion of the
physical map. In general, little is known about the genetic variation or
disease risk models that underlie a positional cloning region, whether
the region has been identiﬁed through prior linkage or restricted
association analysis. Pertaining to the 20q13.1 region, the question of
whether the linkage and association signals result solely from variation
in the HNF4A gene or include other gene locus variants is still
unanswered.
We have screened a 6-Mb region on 20q13.1 for association with
T2DM testing common SNPs identiﬁed in this region under multiple
tests of association. We selected the most signiﬁcant associated SNPs
for replication typing in an independent Caucasian case-control cohort
227J.L. Bento et al. / Genomics 92 (2008) 226–234and performed in silico gene replication analysis of the region using
two public Genome-Wide Association Study (GWAS) data sets.
Results
The goal of this study was to identify gene loci in the human chro-
mosome 20q13.1 interval associated with susceptibility to T2DM. We
developed an SNP map to screen for initial association in a rural Cau-
casian American population recruited from Forsyth and adjacent
counties in North Carolina and then analyzed associated genes for
replication. The screen employed 390 SNPs covering a 5.795-Mb region
(build 36:41.4–47.2 Mb), which we genotyped in a case-control popu-
lation consisting of 300 Caucasian comorbid individuals with T2DM
and end-stage renal disease (T2DM-ESRD) and 310 Caucasian controls
(Table 1). This region of 20q encompasses the highest likelihood region
reported in our earlier genetic linkage study [1], overlaps regions of
strongest evidence for linkage in other linkage studies [19,20], and
includes multiple plausible T2DM candidate genes. Figs. 1A and 1B
illustrate features of the resultingmap. There are 98 annotated gene loci
(NCBI RefSeq 36.2), 77 of which are characterized, nonpseudogenes.
There is a modest-sized bgene desertQ (45.848–46.674 Mb) in the distal
half of the map, ﬂanked by SULF2 and PREX1 genes, containing a single
pseudogene, SRMP1 (spermidine synthase pseudogene 1). SNPs were
placed on the map at a greater density within speciﬁc candidate
diabetogenic genes such as HNF4A (23 SNPs/111 kb) and SLC2A10 (15
SNPs/50 kb). The map has a mean density of 1 SNP/14.9 kb with
maximum inter-SNPdistanceof 46.6 kb (between rs1983and rs244128,
Fig.1A, 42.556Mb) (Supplementary Table 1). Thirteen of 390 SNPswere
inconsistent with Hardy–Weinberg equilibrium (HWE) in controls at a
nominal exact pb0.05 level (exact min p=0.0035). One of these SNPs
was also out of HWE in cases (rs3091566, 45.288Mb,p=0.0074) located
in the EYA2/PRKCBP1 region, an otherwise unremarkable region in this
map (Supplementary Table 1).
Using the Gabriel block deﬁnition [15] with a haplotype frequency
threshold of 1k, the map contains 63 haplotype blocks of membership
of two or more SNPs, with mean size of 27.2 kb (0.277–156.857 kb)
capturing 211/390 (54.1k) of the markers, or 29.6k of the map by
genomic distance. This block structure is partially revealed in Figs. 1A
and 1B at the track labeled jD'j, where the absolute value of the inter-
SNP D' of contiguous SNPs from the control population is shown. The
LD structure present in the cases and controls was compared by
evaluating the differences between contiguous SNP pair D' statistics of
cases and controls, as shown in Figs. 1A and 1B, track jD'j.
Genotype data from cases and controls were tested for association
with T2DM–ESRD under additive trend, dominant, and recessive
models. In Figs. 1A and 1B the -log(p) track is a plot of the association
analysis results for each statistic for every SNP in themap. Eleven SNPs
(0.03k) fall in the bsuggestiveQ category, with single-point test signi-
ﬁcance of p≤0.01, and lie in seven perigenic regions (Table 2).
Repetition of the statistical association tests using a logistic regression
model including a European population substructuremarker of ances-Table 1
Characteristics of the chromosome 20q13.1 SNP map
Total region surveyed 5.795 Mb
Gene loci in region 98
77 characterized, nonpseudogenes
14 predicted genes
7 pseudogenes
Number of SNPs 390
Mean SNP density (min–max inter-SNP) 1 SNP/14.9 kb (0.033–46.6 kb)
Number of blocks 63
Mean length of blocks (min–max) 27.2 kb (0.277–156.857 kb)
Total number of SNPs in blocks 211 (54.1k)
Sum length of all blocks 1714 kb (29.6k)try did not substantively change the results, and suggestive SNPs
remained in this category after adjustment (Table 2).
The associated regions include: (1) the well-studied MODY HNF4A
gene locus at 42.47 Mb, a single SNP with suggestive association
(rs1885088, dominant model, p=0.0073); (2) a region at 44.12 Mb in a
37.5-kb LD block encompassing exons 22–26 of SLC12A5 (potassium–
chloride cotransporter) and the complete NCOA5 (nuclear receptor
coactivator 5) gene, including a single associated SNP (rs9074,
recessive model, p=0.0016); (3) a concentration of three associated
SNPs in CDH22 (cadherin-like 22), located in two haplotype blocks
(44.3 Mb, rs6074069, rs966567, rs3904166, dominant model,
p=0.0019, 0.0014, 0.004, respectively); (4) ELMO2 (engulfment and
cell motility 2), which contains two SNPs in this map, one of which in
intron 13 shows suggestive association (rs2257545, 44.44 Mb,
additive, p=0.0059); (5) SLC13A3 (sodium-dependent dicarboxylate
transporter, member 3) with two intronic SNPs (rs126917, rs2425885,
introns 1 and 5, 44.65–44.69Mb), although not formally located in the
same block; (6) SULF2/gene desert (sulfatase 2) with one SNP
(rs2426039, 46.0 Mb); and (7) PREX1/gene desert (phosphatidylino-
sitol 3,4,5-triphosphate-dependent RAC exchanger 1) with three SNPs
(rs2426039, rs926693, rs3924220, 46.0–46.7 Mb).
The region with the most compelling evidence for association
(p≤0.001) is shown in Fig. 1B, within the 46.0–46.7Mb region 3′ of the
PREX1 gene. The most signiﬁcant SNP is rs3924220 (recessive,
p=0.00099), located 32 kb 3′ distal to the PREX1 gene locus (the
gene is coded on the reverse strand relative to the physical sequence
map bforwardQ direction). This is one of three SNPs in Table 2 that lie in
the 800-kb gene desert region ﬂanked centromerically by SULF2 and
PREX1 at the telomere end. The two SNPs closest to PREX1 are
singletons outside haplotype blocks (rs926693, rs3924220) and the
SNP closest to SULF2 is in a block that encompasses SULF2. The three
SNPsmark independent suggestive point association test signals; they
have at most one ﬂanking SNP with nominal (reduced) signal, and the
association signal is attenuated at more distant SNPs. Linkage
disequilibrium also decays in the two intervals between the three
SNPs as shown qualitatively in Fig. 1B and quantitatively by the
observation that multiple distinct blocks separate rs2426039 from
rs926693 and rs926693 from rs3924220.
Using a step-down permutation analysis, we tested the screening
SNPs for map-level signiﬁcance under strong control of the FWER.
None of the markers satisﬁed the pb0.05 map-level signiﬁcance
criterion for any model class (additive, dominant, recessive). The
effective pseudoindependent Bonferroni factor that would correct the
nominal p values in each class of model tests is ~114–252, very similar
in magnitude to the n=390 total point tests, with assumed linkage
equilibrium.
We tested the top two SNPs in the CDH22 and PREX1 perigenic
regions in an independent replication case–control sample from the
Diabetes Heart Study (DHS) cohort (Table 3). We found that one SNP
was signiﬁcant in the DHS sample at pb0.05 (PREX1 rs926693, DHS
additive, p=0.05, dominant, p=0.031), while the other three SNPs
were not signiﬁcant. For the four SNPs, the differences between the
T2DM–ESRD and the DHS control minor allele frequencies was (−1.1 –
2.9)k, while for cases it was (−0.8− (−5.0))k. The most comparable
frequencies for cases and controls were for the replicated SNP.
Using the summary association statistics from the Diabetes Genetics
Initiative (DGI) and Wellcome Trust Case Control Consortium (WTCCC)
studies we plotted the case-control p values for tests of association
together with our 11 leading SNP screen p values in an integrated
genetic association plot (Fig. 2). The DGI p values are meta-analysis
results combining statistics fromanalysis of approximately 1000match-
ed cases and controls with discordant sibship family-based tests of
association of approximately 330 sibships under a combined Z-score
model, corrected for genomic control inﬂation. TheWTCCC p values are
for additive and genotype tests of association using 2000 T2DM cases
and 3000 combined 1958BBC and UKBS controls [21]. The DGI leading
Fig. 1. SNPmap of 20q13.1. The contiguous 6Mb are shown in proximal and distal 3-Mb panels. The chromosome 20 physical map distance (NCBI build 36) is denoted along the top in
kilobases, followed by the annotated genes in the Genes track, the association analysis for each individual SNP located in the –log(p) track, the difference between inter-SNP D' values
in T2DM–ESRD cases and controls in the jD'j track, the inter-SNP D' values in this region as observed in the control population, the locations of SNPs, and other markers located in the
region. Some SNP marker names have been omitted for clarity. A full listing of all markers can be found in Supplementary Table 1.
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Table 2
The most signiﬁcant association signals detected in the 390-SNP map screen using additive, dominant, and recessive 1 df tests with pb0.01
SNP Position (kb) Nominal
p value
Adjusted
p value
Model Gene locus/map region Gene model
location
Gene model
transcript
rs1885088 42,472,454 0.00731 0.00518 Dominant HNF4A Intron 3 NM_178850
rs9074 44,122,072 0.00159 0.00181 Recessive SLC12A5 3′ UTR NM_020708
rs6074069 44,288,133 0.00185 0.00090 Dominant CDH22 Intron 3 NM_021248
rs966567 44,300,632 0.00136 0.00078 Dominant CDH22 Intron 2 NM_021248
rs3904166 44,306,828 0.00404 0.00237 Dominant CDH22 Intron 1 NM_021248
rs2257545 44,437,195 0.00589 0.00808 Additive ELMO2 Intron 13 NM_133171
rs126917 44,655,342 0.00774 0.00580 Additive SLC13A3 Intron 5 NM_022829
rs2425885 44,693,038 0.00386 0.00070 Recessive SLC13A3 Intron 1 NM_022829
rs2426039 45,978,568 0.00971 0.00828 Additive SULF2; gene desert - -
rs926693 46,512,364 0.00950 0.00868 Additive PREX1; gene desert - -
rs3924220 46,642,852 0.00099 0.00107 Recessive PREX1; gene desert 32 kb 3′ distal NM_02820
The most signiﬁcant test p value is shown, although other models may also be signiﬁcant at this threshold. The adjusted p-value model includes a covariate SNP for European
population stratiﬁcation (rs4988235). The annotation of the location of the SNP is relative to the nearest characterized gene. SNPs in the gene desert region spanned by characterized
genes SULF2 and PREX1 are reported with the closer of the two ﬂanking genes. The gene model position is relative to the gene model transcript (NM sequence accession) shown.
Blocks are counted with two or more SNP members; singleton SNPs are not considered bblocks.Q
229J.L. Bento et al. / Genomics 92 (2008) 226–234candidate region (cluster of 3 SNPs, 44.224 Mb) is located between the
CD40 and the CDH22 gene loci, ~1.5 kb 3′ of CDH22 (lead SNP
rs1321000, p=0.00021). There is a single WTCCC SNP, pb0.01, in the
region between 44.0 Mb and the 3 suggestive CDH22 SNPs at 44.3 Mb
(rs16991026, p=0.0036), which lies in intron 17 of SLC12A5. In contrast,
the lead candidate in WTCCC is in the distal promoter of ELMO2,
approximately 10 kb 5′ of exon 1 (rs1033475, p=9.7 10−5). Other SNPs in
the WTCCC in the gene desert region were signiﬁcant at pb0.01
(rs10211734, 120 kb 5′ of SULF2, p=0.0017; rs11699291, 300 kb 5′ of
PREX1, p=0.0049). For our other leading perigenic regions, there is a
pair of WTCCC SNPs at 44.739–44.805 Mb, near our two SLC13A3 SNPs.
The ﬁrst rs6017968, p=0.0065, is located in intron 1 of SLC13A3, while
the other (rs742321, p=0.0059) is ~60 kb telomeric to the ﬁrst and is 8
kb 3′ of SLC2A10. Therewere no SNPs signiﬁcant at pb0.01 in theHNF4A
perigenic region in either GWAS study. Two of our 11 leading candidate
SNPs are present in the published GWAS results (rs2257545 DGI;
rs966567 DGI+WTCCC), although neither was signiﬁcant in these
studies (pN0.1). We found measurable heterogeneity between the DGI
and theWTCCC study results in this map interval, with the leading ﬁve
perigenic regions at pb0.01 differing between studies. The leading
WTCCC and DGI SNPs are listed in Supplementary Table 2.
In addition to the tests of SNP main effects in the initial screen, we
performed haplotype analyses within the 63 haplotype block regions
of high LD. Six of the 63 blocks (9.5k) showed nominal association at
pb0.05, blocks 22 (SLC12A5), 30 (ELMO2), 33 (ZNF334), 35 (SLC13A3),
48 (SULF2), and 51 (gene desert region) (Table 4). Seven of the 11 most
associated SNPs in Table 2 lie in six distinct haplotype blocks of at least
size 2, but only 3 of these blocks showed nominal association under a
global model of homogeneity in cases and controls using simulation
with haplo.score [22]: block 22 (rs9074), block 30 (rs2257545), and
block 35 (rs126917). The other 3 nominally associated blocks (33, SNPs
rs2780231-rs366860; 48, SNPs rs425433-rs1889177; 51, SNPs
rs6066563-rs2664588) do not contain a suggestive main effects SNPTable 3
Comparison of the DHS cohort replication genotyping results for the most signiﬁcant CDH22
empirical odds ratios under the most signiﬁcant test model
SNP Position (kb) Gene locus/map
region
Cohort Major/m
allele
rs6074069 44,288,133 CDH22 DHS G/A
T2DM–ESRD G/A
rs966567 44,300,632 CDH22 DHS G/C
T2DM–ESRD G/C
rs926693 46,512,364 PREX1; gene DHS A/G
desert DHS A/G
T2DM–ESRD A/G
rs3924220 46,642,852 PREX1; gene DHS T/C
desert T2DM–ESRD T/C(Table 2, pb0.01). Block 48 is a 51.2-kb block that spans introns 5–9 of
SULF2 (global sim p=0.043) containing SNP rs425433, which has a
modest point association under dominant (p=0.02) and additive
(p=0.046) models.
Table 5 shows the detailed haplotype association results for two
SNP haplotype block of ZNF334. The association (global sim,
p=0.00105) is interesting in that neither of the two member SNPs
(rs2780231, rs366860) shows nominal point association with T2DM
under any model (pN0.1). The maximum missing data for either of
these two SNPs in cases or controls is 2.7k andboth SNPs are inHWE in
cases and controls. The global association is entirely driven by a strong
effect in a rare risk haplotype (4k cases vs 1k controls). The
Expectation-Maximization (EM) haplotype frequencies are robust to
bseedingQ with copies of the rare haplotypes (data not shown). This
block encompasses exon 1-intron 2 of ZNF334 (zincﬁnger protein 334),
which is putatively a transcriptional factor or cofactor.
Discussion
We have carried out an initial screen and replication analysis for
T2DM–ESRD susceptibility genes in a 6-Mb region of 20q13.1, a speciﬁc
region implicated in previous linkage analyses, which increases prior
belief of association.Wedetected 53 of 390 SNPs (13.6k) that exhibited
nominal association in one or more point tests of association (MIN3
statistic) under standard 1 df disease models (additive, dominant,
recessive). At a more stringent signiﬁcance level of pb0.01, 11 SNPs
(0.03k) in seven perigenic regions retained signiﬁcance. The propor-
tions of signiﬁcant SNPs at =0.05 were 6.4, 7.9, and 5.6k (additive,
dominant, and recessive, respectively) and 1.5, 1.3, and 0.8k, res-
pectively, at =0.01, comparable or very slightly elevated relative to the
expectation under the complete null hypothesis for each class of
independent tests assuming linkage equilibrium. The very slight
increase could reﬂect an increased rate of false positives stemmingand PREX1 perigenic SNPs from the T2DM–ESRD case–control screening analysis with
inor Model Allele frequency
controls, cases)
p value OR (95k CI)
Dominant 0.212, 0.199 0.681 0.89 (0.45−1.74)
Dominant 0.197, 0.249 0.00185 4.87 (1.63−14.58)
Dominant 0.232, 0.229 0.885 1.04 (0.60−1.82)
Dominant 0.229, 0.276 0.00136 3.51 (1.56−7.92)
Additive 0.430, 0.475 0.05 1.20 (0.99−1.44)
Dominant 0.430, 0.475 0.031 1.37 (1.03−1.83)
Additive 0.441, 0.483 0.00950 1.35 (1.08−1.70)
Recessive 0.224, 0.244 0.1284 1.17 (0.96−1.44)
Recessive 0.195, 0.265 0.00099 1.73 (1.25−2.40)
Fig. 2. Integrated genetic association analysis of 20q13.1. The –log10(p) for three separate
T2DM case–control studies plotted against the chromosome 20 physical map position in
kilobases are shown. The current study (T2DM–ESRD 11 SNP) shows the top 11 SNPs
from Table 2. DGI Meta-Analysis, the meta-analytical results from the Diabetes Genetics
Initiative (Lund-Broad-Novartis), 1520 SNPs; WTCCC, the Wellcome Trust Case Control
Consortium additive (1 df) and genotype (2 df) results for 1074 SNPs. See also
Supplementary Table 2.
Table 5
Haplotype analyses for the two-SNP haplotype block (rs2780231, rs366860) of ZNF334
Haplotype Frequency Hap score p value
Cases Controls Combined Simulated Global
CT 0.45 0.47 0.46 −0.88 0.382 0.00105
TG 0.51 0.51 0.51 −0.11 0.922
CG 0.04 0.01 0.02 3.64 0.0002
T2DM–ESRD vs controls (cases n=300, controls n=310).
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represent common variants that contribute net modest additional
genetic risk to T2DM–ESRD susceptibility. Inclusion of a marker of the
major European axis of population ancestry (rs4988235) in our statis-
tical models had little effect on our screening population association
results, validating our belief that the strategy of simultaneous
recruitment of cases and controls from the same rural regional Eastern
Atlantic Caucasian population minimized systematic ancestry differ-
ences between cases and controls. Noneof the SNPs in the initial screen
reached rigorous Bonferroni or permutation-based map-level signiﬁ-
cance in point tests of association corresponding to 390 tests for each
genetic model or the composite MIN3 statistic. This is unsurprising
since the screening studywas not powered for a signiﬁcance threshold
of p=10−5 under a commonvariantmodelwith odds ratio ~1.3–1.5.We
supplemented the screen by testing our leading SNPs in a replication
case-control cohort and integrated published GWAS data for this
region also.
We tested 4 of our leading candidate SNPs from the most highly
associated PREX1/gene desert and CDH22 regions in a larger indepen-
dent diabetic case-control cohort (DHS) for replication. One SNP in the
PREX1/gene desert locus was signiﬁcant at p=0.05, increasing our
conﬁdence that this SNP signals a perigenic region that contains trueTable 4
Haplotype blocks in relative map order with nominal signiﬁcance (pb0.05) under a
global score test of association using simulation
Block 5′ SNP 3′ SNP 5′ SNP
position
3′ SNP
position
Block
size
Block
length
(kb)
Global
sim
p value
22 rs2297200 rs2868764 44,117,933 44,155,418 10 37.486 0.027*
30 rs1044369 rs2257545 44,420,725 44,437,195 3 16.471 0.038*
33 rs2780231 rs366860 44,569,851 44,574,807 2 4.957 0.0011
35 rs6066029 rs126917 44,650,935 44,655,342 2 4.408 0.012*
48 rs425433 rs1889177 45,729,687 45,744,925 2 15.239 0.043
51 rs6066563 rs2664588 46,012,126 46,014,041 2 1.916 0.034
Association tests were performed using haplo.score [17], retaining haplotypes with a
frequency of 1k or greater. Positions of SNPs that start (5′) or end (3′) a block are for
chromosome 20 forward-strand physical map coordinates, genome build 36. sim,
simulated.
* Value contains at least one SNP with signiﬁcance pb0.01 in one or more marginal
tests of association.variants associated with T2DM. By integrating analysis of the results
from two separate GWAS data sets, wewere able to infer replication in
at least one GWAS within all of our perigenic regions with the
exception (ironically) of HNF4A, the MODY risk locus and best studied
of T2DM candidate genes in this interval. Two of our 11 leading
candidate SNPs are present in the published GWAS results, although
neither was signiﬁcant in these studies. This suggests either that there
is allelic heterogeneity at the associated gene loci and different case-
control populations are detecting different frequent gene variants, or
that the true variants are the same but differing patterns of linkage
disequilibrium and SNP selection biases result in differing lead study
SNPs for each of the predisposing genes.
We chose to perform multiple tests of association at each SNP to
maximize the likelihood of detecting association under an unknown
disease model of risk. The choice of association test statistic requires a
balance between power and tolerance of type 1 error, and test perfor-
mance will vary subtly with the latent genotype risk ratios, level of
genotyping error, and point values of Hardy-Weinberg disequilibrium
[23–26]. Allelic and genetic heterogeneity in the regionmaymean that
no single test statistic is optimal for detecting all contributing alleles or
genes, even if the variants are relatively common. The downside of
usingmultiple tests is the increased probability of false positive results,
albeit the test statistics are mutually correlated.
The most signiﬁcant SNP from the initial screen that was validated
in the DHS replication cohort (rs926693, mean minor allele frequency
47.9k cases, 43.5k controls, additive model), lies in an 800-kb gene
desert of the map, approximately 160 kb 3′ of the PREX1 gene, with an
odds ratio of 1.35 in the T2DM–ESRD screening cohort and 1.20 in the
DHS replication. Two other SNPs also lie in this same gene desert
region (45.9–46.7 Mb, ﬂanked by SULF2 and PREX1) but the leading
SNP from the screen was not signiﬁcant in replication. The WTCCC
GWAS analysis also found one SNP at pb0.01 in this desert region.
PREX1 does not have an obvious biological role in T2DM, but its
protein product is involved in cell signaling pathways as a guanine
nucleotide exchange factor for the Rho family of small GTP-binding
proteins [27]. There are other clusters of spliced ESTs in this desert
region that havenot been characterized,which could also be functional
sites of variation. We checked for the possibility of artifactual asso-
ciation and HWE results, but the mapped PREX1 SNPs do not lie in any
LINE or SINE human repeats or long segmental duplications [28].
Our screeningmap identiﬁed signals at two other perigenic regions
that contained the most highly associated SNPs in this interval in both
of the GWAS studies, ELMO2 at 44.43 Mb (WTCCC) and CDH22 at 44.3
Mb (DGI). The CDH22 gene locus contains three suggestive SNPs in two
blocks, although two of these were not signiﬁcant in DHS replication.
CDH22 encodes a calcium-dependent cell adhesion protein that may
play a role in morphogenesis and tissue development and could be
involved in the development of diabetes-related tissues, e.g., pancreas
and liver [29].
HNF4A gene SNPs, the subject of recent reports of association with
T2DM [7,8], generally showed modest association, although one SNP
did reach suggestive signiﬁcance (rs1885088) in the initial screen.
Association of HNF4Awith T2DM in this population has been explored
in a previous publication [9] but was tested only under an additive
model. The more extensive analysis here suggests that SNP dominant/
recessive effect models aremore important than purely additive in our
231J.L. Bento et al. / Genomics 92 (2008) 226–234population and screening map. HNF4A was not signiﬁcant in either
GWAS analysis at pb0.05.
The question of why our study results seem to corroborate genes in
both GWAS studies separately and why there is noticeable hetero-
geneity between the GWAS analyses is still open. The lack of a stronger
GWAS signal at HNF4A is also intriguing. While the GWAS analyses did
ﬁnd similar genes in the extreme tail of the whole-genome statistics
[30,31] this study suggests that there is detectable genetic hetero-
geneity lower in the statistical association ranking, concomitant with
weaker effect sizes. This could be a result of the differing clinical
characteristics of the case–control populations or may be due to
differing ancestral genetic background within the broad Caucasian
race category, exposing the importance of different gene variants and
shufﬂing of their relative importance. The DHS cases had a largermean
bodymass index (BMI) (33.0 kg/m2) than T2DM–ESRD screening cases
(28.5), WTCCC (30.7), or DGI (28–29 range), while the T2DM–ESRD
cases had ameandiabetes duration of N15 years compared toDHS (11.2
years), WTCCC (8.3 years), and DGI (5–9 years range).
Other perigenic regions with suggestive association from the initial
screen were exons 22–26 of the SLC12A5 gene and the entire NCOA5
gene at 44.12 Mb and SLC13A3 at 44.65–44.69 Mb. SLC12A5 is a
potassium chloride cotransporter that normally lowers intracellular
chloride concentrations below the electrochemical equilibrium poten-
tial [32] but is not expressed in tissues of direct interest in T2DM or
nephropathy. NCOA5 encodes a coregulator for the α- and β-estrogen
receptors [33]. α-estrogen receptor knockout mice are insulin
resistant, have impaired glucose tolerance, and are obese [34].
NCOA5 acts as a corepressor and coactivator of theα-estrogen receptor.
Our group previously reported evidence of association of the
chromosome 20q PTPN1 gene with T2DM and measures of glucose
homeostasis [10,11]. The evidence of association with T2DM observed
in this study, e.g., CDH22, are comparable to the odds ratios observed
with PTPN1 (1.3–1.5) and consistent with multiple genes in this region
contributing risk to T2DM.
Our results are consistent with previous studies and replicate prior
association reports on the genes HNF4A, CDH22, ELMO2, and PREX1.
There is an extensive literature on the association of HNF4A in MODY
and older onset T2DM [7–9]. A recent study [12] of 675 Japanese cases
of T2DM and 474 controls across a 17.7-Mb region of 20q at a com-
parable density (1 per 15.4 Mb vs 14.7 Mb here) found maximal asso-
ciation with the LBP gene (lipopolysaccharide binding protein), which
is 5 Mb centromeric to our map. However, they found a secondary
association of diabetes with ELMO2 (rs2297056, p=0.010, and
rs2257545, p=0.006) and PREX1 (rs13044736, p=0.006) genes. Four
recent GWAS studies found consistent 20q association at rs6030447
(odds ratios 0.99–2.53), which is located in the protein tyrosine
phosphatase, receptor type T gene (PTPRT), 1 Mb centromeric to our
map [35–38]. Since our map boundaries were originally deﬁned based
on a LOD-1 maximal linkage criterion [2], it is possible that this gene
could also contribute to our diabetes linkage signal and association
also.
Haplotype association analysis was performed for all 63 haplotype
blocks in the map. Six of 63 blocks showed nominal global association
(pb0.05) although no block was signiﬁcant at the n=63 Bonferroni-
corrected level. Only 7 of the 11 associated SNPs fell in haplotype
blocks, and only 3 of these were nominally associated. This suggests
that the association signals of the 4 remaining SNPs were partially and
completely scrambled in the three nonassociated haplotype blocks.
The 10-SNP block 22 containing rs9074 (SLC12A5–NCOA5) showed
evidence of a frequent risk and a protective haplotype, the risk haplo-
type association being largely determined by the rs9074 allele tag. The
two other nominally associated blocks contain associated SNPs
displaying haplotype association patterns that suggest the association
is largely driven by the singly associated SNP. We also found a 2-SNP
haplotype block (rs2780231, rs366860) contained in the ZNF334 gene
locus for which neither SNP had suggestive or nominal point levels ofsigniﬁcance, but which displayed the most signiﬁcant block associa-
tion. The association appears to result from a rare risk haplotype (4k
cases versus 1k controls). There were also two other blocks devoid of
associated SNPs that showed more modest haplotype association
(p=0.03, 0.04).
We compared our map coverage with another recently published
T2DM GWAS [39], which used a HumanHap300 multiplex assay
(Illumina, San Diego, CA, USA) containing 317,503 SNPs. Based on our
map interval ([2], build 36, chr20:41415109–47243708) the Human-
Hap300 assay contains 701 SNPs, giving a relative physical coverage of
1 per 8.3 kb (5.828 Mb/701) versus our 1 per 14.9 kb for 40k greater
physical density. The HumanHap300 coverage is 10.7k higher than
the 633 expected SNPs from the mean nonredundant autosomal
density of HumanHap300 (308,330 SNPs spanning 2.868 Gb). We
estimated our map tag coverage using HapMap data. In release 22 of
HapMap (March 2007) the same map interval contains 11,947 typed
SNPs; 336/390 of our map SNPs were typed in this release. Haploview
identiﬁes a minimal pairwise tagSNP set of 1343 in this interval for the
30 CEPH families, tagging 4965 SNPs with MAF N0.05 at r2 N0.8. Of the
1343 tagSNPs, 98 are included in our map. At r2 N0.8, the 336
HapMap-included SNPs in our map tag 2020 HapMap SNPs at MAF
N0.05, for a relative map coverage of 40.7k compared to release 22
HapMap, while at r2 N0.5, the relative coverage is 56.5k (2804/4965).
Since our map contains 54 additional non-HapMap-typed SNPs, the
map coverage will be larger than these estimates.
Power to detect variants is an important consideration during the
design of any genetic epidemiological study. The power here is sufﬁ-
cient to detect reliably variants with relatively large effect sizes of an
odds ratio of ~1.5, comparable to effect size for the recently discovered
T2DM susceptibility gene TCF7L2, transcription factor 7-like 2 [40], or
very frequent variants (N10k). This is a screening study designed to
identify variants for replication testing. For an odds ratio of ~1.3
(comparable to the functional candidate gene PPARG [41]), nominal
power is low, but this is likely to be an underestimate of effect size of
one or more loci in this region, given the prior replication of linkage
signals in multiple studies, which are typically underpowered for
frequent variants of modest effect. Furthermore, the study design
herein also assumes that there are common variants (MAF N10k) that
contribute to disease risk. It will not detect genes for which the sus-
ceptibility is distributed among rare variants with a high degree of
allelic heterogeneity. The controls in this study were not tested for
diabetes, and the small proportion of undiagnosed T2DM cases may
have reduced our power and led to underestimation of odds ratios.
Since the case population was ascertained by diagnosis of T2DM
with ESRD with mean duration of diabetes N15 years, there is a
possibility that we have detected diabetic nephropathy/ESRD-
predisposing alleles. Since the DHS replication T2DM cases were
recruited with exclusion of nephropathy, the replication of the
PREX1/gene desert region suggests that at least this region is
associated with the primary T2DM clinical phenotype. Based on
the expression and known biology of these gene loci, SLC13A3 is the
most likely of the genes to affect renal function, although we cannot
absolutely exclude any of the genes. This is a high-afﬁnity
transporter of Krebs cycle dicarboxylate intermediates, which
localizes to the basolateral membrane of the human renal proximal
tubule [42]. Further study in a diabetic population with clear
adjudicated lack of nephropathy will be necessary to answer fully
the question of disease phenotype speciﬁcity. Other recent large
GWAS case–control population studies of T2DM did not enforce
case-exclusionary criteria based on a clinical diagnosis of diabetic
nephropathy.
In summary,wehave analyzed an important linkage region for type 2
diabetes and have replicated and extended the analysis of genes pre-
viously reported to be associated with T2DM. We have also identiﬁed
new loci that warrant further detailed analysis. While these genes may
not have the strongest effect genome-wide, their consistent replication
232 J.L. Bento et al. / Genomics 92 (2008) 226–234suggests that more than one gene in this region contributes to T2DM–
ESRD pathology.
Materials and methods
Subjects
Samples for initial screen consisted of 300 unrelated Caucasian
T2DM patients with ESRD and 310 randomly ascertained unrelated
Caucasian subjects without known diabetes at recruitment. Cases
and controls were recruited simultaneously from the 10-county
region around Forsyth County, North Carolina, USA. All subjects had
parents who were born in North Carolina. The diabetes cases are
referred to herein as bT2DM–ESRDQ; their ascertainment and
recruitment have been previously described in detail [10]. Ascertain-
ment of cases based on a diagnosis of diabetes-related ESRD results
in a group of cases with one of the most prevalent and lethal
complications of diabetes. While random ascertainment of the
control group may lead to some loss of power due to undiagnosed
or future development of diabetes, this ascertainment scheme is
more robust to potentially unperceived population stratiﬁcation. The
subjects in this case–control sample are independent of, though
ascertained and recruited in an identical manner to, family samples
described by [1]. T2DM–ESRD subjects had a mean age at diagnosis
of diabetes of 46.5 12.8 years, mean BMI at recruitment of 28.5 7.0,
mean duration of diabetes greater than 15 years, and mean HbA1c of
8.6k. The Caucasian control individuals had a mean age of 45.8 years
with a mean BMI of 25.7.
Replication genotyping of selected SNPs was performed in T2DM-
affected probands from the DHS [43]. The DHS is a single-center
family-based study of atherosclerosis in T2DM-enriched families.
Only the proband of each family was used as a case subject. Four
hundred seventy T2DM-affected proband cases were genotyped
(mean age of diagnosis of diabetes 51.6 years, mean BMI 33.0 kg/m2,
mean duration of diabetes 11.2 years, mean HbA1C 7.5k). Unlike the
T2DM–ESRD cases, DHS participants were recruited with an
exclusion of diabetic nephropathy. As a control population for this
group we genotyped 442 unrelated healthy self-declared Caucasian
subjects (mean age 57.3 years, mean BMI of 28.1).
SNP selection and genotyping
The 20q13.1 region mapped in this study is identical to that
described in [2] and encompasses the highest likelihood linkage
region from the combined analyses carried out by the NIDDK-
supported International Type 2 Diabetes Genetic Mapping Consor-
tium (data not shown). SNPs were selected from HapMap, NCBI
dbSNP, and Appelera/Celera Discovery System to map the build 36
region (identical in build 35) chr20:41415109–47243708;
NT_011362.9:7034610–12863209 (5,828,600 bp) with a bias for
validated SNPs. Minor allele frequencies ranged from 0.030 to 0.50 in
controls (median=0.30) and from 0.027 to 0.50 in cases (med-
ian=0.31) (Supplementary Table 1). All SNP ampliﬁcation primers
were designed for amplicon uniqueness and mapped using NCBI
BLAST/UCSC BLAT. Primers that mapped to low-copy-number
segmental duplications or interspersed repeats were redesigned or
alternative SNPs selected if necessary. Gene annotations were
extracted from NCBI contig NT_011362, version 9. The SNP map
(Figs. 1A and 1B) was drawn using the Perl program MAPPLOT
(unpublished work). Within-European stratiﬁcation was tested using
SNP rs4988235 [44], which is a perfect marker of lactase persistence
and highly informative for European North–South ancestral gradient.
Genotyping was performed on a Sequenom MassArray genotyp-
ing system using methods previously described [10,45,46]; 331 SNPs
were typed with hME chemistry, 50 with iPLEX, and 9 with both.
Speciﬁc primer sequences are available upon request.Quality control
Manual review
Each genotype spectrumwas manually reviewed by a lab member
very experienced with the Sequenom platform. During review,
doubtful genotypes were preferentially changed to missing rather
than risk misclassiﬁcation.
QC duplicates and sample blanks
In control plates, two samples were duplicated at ﬁve separatewell
addresses, while in cases, eight samples were duplicated at two well
addresses. Each plate also contained two water blanks. If there were
more than one discordant genotype in QC replicates, or genotype
signals were seen in the negative control blank wells, the SNP geno-
typing was rejected and repeated. Depending on the type of QC error,
SNPs were repeated in single or multiplex mode and typed/reviewed
by a second experienced lab member.
Hardy–Weinberg equilibrium
Genotyped SNPs were tested for departures from HWE using an
exact test [47]. SNPs not in HWEwere repeated. After repeat typing,we
rejected any SNP for which the exact test was signiﬁcant at pb0.001 in
controls, resulting in rejection of 11 SNPs. In 2 SNPs (rs733379 controls
and rs2297201 cases) the HWE p value was close to the 0.001 cutoff,
and the SNP genotype patterns were manually reviewed.
Missing data
For any SNP missing N10k of data or a Hardy–Weinberg p value of
b0.001 in cases or controls, an experienced lab member reviewed the
two-dimensional genotype cluster plots to verify patterns and cluster
separation. The maximum of missing data in controls was 14.5k
(mean 2.7k) and in cases 13k (mean 2.9k), with 16 SNPs missing
N10k of data in cases. Of these 16 SNPs, only 1 had a HWE test
signiﬁcance of pb0.05 in cases (rs1984076), and only 1 showed
evidence of association pb0.05 (1 df recessive model, rs2425941). In
situations in which there was any doubt in the genotype calling, SNP
cluster plots were manually reviewed for adequate cluster separation.
While departure from HWE may indicate unresolved problems with
assay accuracy, it may also reﬂect true disease association. The
association test statistics chosen are somewhat robust to departures
from HWE [24], but may still lead to inﬂated type 1 error rates under
circumstances in which genotypes are differentially misclassiﬁed
between cases and controls. All of the most signiﬁcant bsuggestiveQ
associated SNPs were reviewed.
Statistical analysis
The pairwise linkage disequilibrium statistics D' and r2 were
calculated using Haploview [48] and the haplo.em function in the R
package haplo.stats (version 1.3.1, Mayo Clinic/Foundation, http://
mayoresearch.mayo.edu/mayo/research/schaid_lab/software.cfm). All
SNPs were tested for association in the case–control study under the
following 1 df models: Cochran–Armitage additive trend (1 df, scores
0, 1, 2), dominant (1 df), and recessive (1 df). We ranked SNPs based on
the minimum p value of the preceding three tests (MIN3 statistic).
This robust statistic was motivated by the MAX3 statistic used by [23]
for case–control association tests using the Cochran–Armitage test, in
which the optimal relative score for heterozygote in the three
genotype classes (AA, Aa, aa) is unknown. We estimated the power
to detect nominal levels of association under Cochran–Armitage score
test statistics using the reﬁnement described in [23] derived by Slager
and Schaid [22,25]. The parameters used were selected to be realistic
of a T2DM complex disease common risk locus under a multiplicative
disease risk model. Assuming a T2DM disease prevalence of 10k and
multiplicative genotype risk ratio of 1.5 or 1.3, the power of the screen
to detect association at a nominal SNP signiﬁcance level of 5k is
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frequency of 10k, and respectively 91.7 or 56.3k for risk allele fre-
quency equal to 20k. Under different disease models, the dominant
and recessive score tests can outperform the additive trend.
We tested whether population stratiﬁcation could account for our
case–control association results using a logistic regressionmodel incor-
porating the within-Europeanmarker of substructure (rs4988235) as a
covariate to the SNP main effect term.
Two methods were used to adjust for type 1 error rates across
multiple single SNP tests of association. We ﬁltered based on the
heuristic criterion of MIN3≤0.01 to obtain a set of SNPs bsuggestive of
association,Q i.e., at least one point test of association signiﬁcant at the
0.01 level. To correct for map-level multiple testing we evaluated the
association results using a permutation analysis to simulate the null
joint distribution of marker statistics and applied step-down analysis
on the ordered, adjusted p values for each separate class of tests. This
procedure adjusts for multiple map tests while maintaining control
over the family-wise error rate at any desired level of signiﬁcance.
We identiﬁed haplotype blocks in the combined case+control
cohort under the null hypothesis of no differences in haplotype
structure between cases and controls, for map SNPs with a minor
allele frequency N1k and a minimum haplotype frequency threshold
of 1k, using the Gabriel 95k conﬁdence interval algorithm [15]
implemented in Haploview [48]. Haplo.score was used to test for
case–control association of haplotypes within these haplotype blocks
in a manner similar to that described in Bento et al. [10], skipping
haplotypes with frequencies b0.01. The map-wide signiﬁcance for a
single haplotype block global test of signiﬁcance was set to the
Bonferroni-corrected value of 0.05/63 total blocks=0.0008. R version
2.3 (http://www.r-project.org) was used for all statistical analyses
other than where explicitly mentioned.
GWAS data sets
We downloaded two publicly available T2DM case–control data
sets to test replication of our results in additional populations of larger
sample size. The DGI is a collaboration between Lund University,
Broad Institute, and Novartis Institutes for Biomedical Research. Full
details of patient recruitment and the primary analysis are available at
bWhole Genome Scan for Type 2 Diabetes in a Scandinavian CohortQ
http://www.broad.mit.edu/diabetes/scandinavs/index.html [31]. We
also used results from the WTCCC (http://www.wtccc.org.uk/). Full
study and analysis details are available at this site and in the compa-
nion publication [30]. We applied a genome coordinate ﬁlter to the
data sets to identify the relevant region.
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